Roche Holding AG (ROG.SW)
- Previous Close
229.70 - Open
226.60 - Bid 223.60 x --
- Ask 223.80 x --
- Day's Range
223.20 - 226.70 - 52 Week Range
217.00 - 293.55 - Volume
327,518 - Avg. Volume
1,457,503 - Market Cap (intraday)
180.634B - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
15.65 - EPS (TTM)
14.31 - Earnings Date Feb 1, 2024
- Forward Dividend & Yield 9.60 (4.18%)
- Ex-Dividend Date Mar 14, 2024
- 1y Target Est
277.06
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
www.roche.com103,605
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ROG.SW
![[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19](https://s.yimg.com/uu/api/res/1.2/3tujng84jArYxPYsssA04w--~B/Zmk9ZmlsbDtoPTYzO3B5b2ZmPTA7dz04NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/84b0110bbf60eb8397db0461bc3549c4.cf.webp)
Performance Overview: ROG.SW
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ROG.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ROG.SW
Valuation Measures
Market Cap
185.31B
Enterprise Value
205.59B
Trailing P/E
16.05
Forward P/E
13.07
PEG Ratio (5yr expected)
1.56
Price/Sales (ttm)
3.06
Price/Book (mrq)
6.25
Enterprise Value/Revenue
3.40
Enterprise Value/EBITDA
11.09
Financial Highlights
Profitability and Income Statement
Profit Margin
19.02%
Return on Assets (ttm)
12.44%
Return on Equity (ttm)
37.86%
Revenue (ttm)
60.44B
Net Income Avi to Common (ttm)
11.5B
Diluted EPS (ttm)
14.31
Balance Sheet and Cash Flow
Total Cash (mrq)
10.51B
Total Debt/Equity (mrq)
92.75%
Levered Free Cash Flow (ttm)
8.6B
Research Analysis: ROG.SW
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: ROG.SW
ROG.SW does not have Company Insights